A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy

Nanomedicine

Volumn 10, Issue 2, 2015, Pages 241-251

  Pan, Dipanjan ^a,b   Kim, Benjamin ^a   Hu, Grace ^a   Gupta, Deepti Sood ^a   Senpan, Angana ^a   Yang, Xiaoxia ^a   Schmieder, Anne ^a   Swain, Corban ^a   Wickline, Samuel A ^a   Tomasson, Michael H ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Illinois at Urbana Champaign   (United States)

Author keywords

c Myc inhibitor; melanoma; nanotherapy; prodrug

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOGENIC C MYC INHIBITOR; UNCLASSIFIED DRUG; 5-(4-ETHYLBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE; MYC PROTEIN; NANOPARTICLE; PRODRUG; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL LINE; NANOMEDICINE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MOUSE; PROCEDURES; RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MELANOMA; MICE; NANOMEDICINE; NANOPARTICLES; PRODRUGS; PROTO-ONCOGENE PROTEINS C-MYC; RATS; THIAZOLES;

EID: 84921503293     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.101     Document Type: Article

References (28)

1. Gearhart J, Pashos EE, Prasad MK. Pluripotency redux-advances in stem-cell research. N. Engl. J. Med. 357, 1469-1472 (2007).
2. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 277, 1-14 (2001).
3. Cotterman R, Jin VX, Krig SR et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 68(23), 9654-9662 (2008).
4. Schlagbauer-Wadl H, Griffioen M, van Elsas A et al. Influence of increased c-Myc expression on the growth characteristics of human melanoma. J. Invest. Dermatol. 112(3), 332-336 (1999).
5. Kraehn GM, Utikal J, Udart M et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer 84(1), 72-79 (2001).
6. Chana JS, Grover R, Wilson GD et al. The prognostic importance of c-myc oncogene expression in head and neck melanoma. Ann. Plast. Surg. 47(2), 172-177 (2001).
7. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2), 193-205 (2003).
8. D'Agnano I, Valentini IA, Fornari C et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene 20(22), 2814-2825 (2001).
9. Chen Z, Zeng H, Guo Y et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J. Exp. Clin. Cancer Res. 29, 151 (2010).
10. Soucek L, Jucker RL, Panacchia R, Ricordy F, Tatò SN. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62(12), 3507-3510 (2002).
11. Berg T, Cohen SB, Desharnais J et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl Acad. Sci. USA 99(6), 3830-3835 (2002).
12. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22(40), 6151-6159 (2003).
13. Mustata G, Follis AV, Hammoudeh DI et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J. Med. Chem. 52(5), 1247-1250 (2009).
14. Prochownik EV, Giap C, Lazo JS, Yin X. US7026343: Improved low molecular weight myc-max inhibitors. (2006).
15. Wang H, Hammoudeh DI, Follis AV et al. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 6(9), 2399-2408 (2007).
16. Lin CP, Liu JD, Chow JM, Liu, CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18(2), 161-170 (2007).
17. Caruthers SD, Cyrus T, Winter PM, Wickline SA, Lanza GM. Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(3), 311-323 (2009).
18. Pan D, Sanyal N, Schmieder AH et al. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine 7(10), 1507-1519 (2012).
19. Burke J, Dennis E. Phospholipase A2 biochemistry. phospholipase A2 biochemistry. Cardiovasc. Drugs Ther. 23, 49-59 (2009).
20. Zhou HF, Yan H, Senpan A et al. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 33(33), 8632-8640 (2012).
21. Arik D, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control. Release 126, 1-9 (2008).
22. Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control. Release 119, 86-93 (2007).
23. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim. Biophys. Acta 1609(1), 95-101 (2003).
24. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jørgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome forming prodrugs. J. Med. Chem. 47(7), 1694-1703 (2004).
25. Jensen SS, Andresen TL, Davidsen J et al. Secretory phospholipase A2 as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer ether lipids. Mol. Cancer Ther. 3(11), 1451-1458 (2004).
26. Andresen TL, Jensen SS, Kaasgaard T, Jørgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr. Drug Deliv. 2(4), 353-362 (2005).
27. Peters G, Møller M, Jørgensen K, Ronnholm P, Mikkelsen M, Andresen T. Secretory phospholipase A2 hydrolysis of phospholipid analogues is dependent on water accessibility to the active site. J. Am. Chem. Soc. 129(17), 5451-5461 (2007).
28. Pan D, Schmieder AH, Wang K et al. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v) β?-targeted theranostic nanoparticles. Theranostics. 4(6), 565-578 (2014).